Diabetic patients with normal baseline renal function are at increased risk of developing contrast-induced nephropathy post-percutaneous coronary intervention

Singapore Medical Journal

Volumn 50, Issue 3, 2009, Pages 250-254

  Chong, Eric ^a   Poh, K K ^b   Shen, L ^b   Chai, P ^b   Tan, H C ^c  

^a ALEXANDRA HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c Cardiology Department   (Switzerland)

Author keywords

Contrast induced nephropathy; Diabetes mellitus; Percutaneous coronary intervention; Renal function

Indexed keywords

ACETYLCYSTEINE; CREATININE; IOHEXOL; SODIUM CHLORIDE; CONTRAST MEDIUM;

ADULT; ARTICLE; COHORT ANALYSIS; CONTRAST INDUCED NEPHROPATHY; DEMOGRAPHY; DIABETIC PATIENT; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INSULIN TREATMENT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE EVALUATION; PROPHYLAXIS; REHYDRATION; SMOKING; STATISTICAL ANALYSIS; AGED; ANALYSIS OF VARIANCE; CHEMICALLY INDUCED; DIABETES MELLITUS; KIDNEY DISEASES; MIDDLE AGED; RISK FACTOR; SINGAPORE; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; CONTRAST MEDIA; DIABETES MELLITUS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; RISK FACTORS; SINGAPORE; TIME FACTORS; ANGIOPLASTY, BALLOON, CORONARY;

EID: 65949120015     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors and relationship to mortality. Am J Med 1997; 103:368-375 (Pubitemid 27506242)
2. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 hours of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36:1542-1548
3. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44:1393-1399
4. McCullough PA. Beyond serum creatinine: defining the patient with renal insufficiency and why? Rev Cardiovasc Med 2003; 4 Suppl 1: S2-6.
5. Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001; 52:409-416
6. Mangano CM, Diamondstone LS, Ramsay LG, et al. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes and hospital resource utilization. The Multicenter Study of Postoperative Ischemia Research Group. Ann Intern Med 1998; 128:194-203.
7. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent- associated nephrotoxicity. J Am Coll Cardiol 2002; 40:298-303.
8. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-336
9. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW . Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89:356-358 (Pubitemid 34113804)
10. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systemic review of angiographic contrast media in high risk patients. Kidney Int 2005; 68:2256-2263 (Pubitemid 43117802)
11. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349:1333-1340
12. Rossert J, Fouqueray B. Screening and management of patients with early chronic kidney disease. Acta Diabetol 2004; 41:S6-12. (Pubitemid 38387624)
13. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention. Circulation 2001; 103:3019-3041
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1):S1-237.
15. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41:47-55.
16. Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol 2008; 51:701-707
17. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259-2264
18. Gruberg L, Dangas G, Mehran R, et al. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv 2002; 55:66-72.
19. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47:254-261
20. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989; 320:143-149
21. Kolonko A, Kokot F, Wiecek A. Contrast-associated nephropathy-old clinical problem and new therapeutic perspectives. Nephrol Dial Transplant 1998; 13:803-806 (Pubitemid 28119084)
22. Hardiek KJ, Katholi RE, Robbs RS, Katholi CE. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. J Diabetes Complications 2008; 22:171-177
23. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast- agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343:180-184
24. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent- associated nephrotoxicity. J Am Coll Cardiol 2002; 40:298-303.
25. Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A randomized comparison of 3 preventive strategies. Circulation 2007; 115:1211-1217
26. Aguiar-Souto P, Valero-González S, Domínguez JF. N-Acetylcysteine and contrast-induced nephropathy. N Engl J Med 2006; 355:1497-1498 (Pubitemid 44511570)
27. Turcot DB, Kiernan FJ, McKay RG, et al. Acute hyperglycemia: implications for contrast-induced nephropathy during cardiac catheterization. Diabetes Care 2004; 27:620-621
28. Rudnick M., Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? Clin J Am Soc Nephrol 2008; 3:263-272